AVALO THERAPEUTICS, INC. Contingent Consideration Classified as Equity, Fair Value Disclosure
AVALO THERAPEUTICS, INC. (AVTX) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $0 as of 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2019-03-18
- 2018-12-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $0.00.
- 2018-09-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $0.00.
- 2018-06-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $0.00.
- 2018-03-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $2.66M.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-18 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-13 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 |
| 2018-03-31 | $2.66M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $2.66M 10-K · filed 2019-03-18 |
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |